About
This medical tool provides physicians with predictive models for retroperitoneal and extremity sarcoma patients. It estimates overall survival and disease-free survival, serving as an informative resource to enhance physician predictive capabilities.
What's New in SARCULATOR
3.0.2
May 1, 2026
Sarculator now includes BayeSarc, a new Bayesian sequential-learning model for prognosis prediction in patients with extremity soft-tissue sarcoma.
Developer apps
FAQ
What is SARCULATOR used for?
SARCULATOR is an informative tool for physicians to improve their predictive capability regarding survival rates for patients with retroperitoneal and extremity sarcomas.
Does SARCULATOR make clinical decisions?
No, SARCULATOR is not meant to make clinical decisions. Its clinical usefulness has not been tested, and it serves solely as an informative tool for physicians.
What types of predictions can SARCULATOR provide?
SARCULATOR can provide predictions for 5-year overall survival and disease-free survival in primary resected retroperitoneal sarcoma patients, as well as 5- and 10-year overall survival and cumulative incidence of distant metastasis in primary resected extremity sarcoma patients.
Is SARCULATOR available on Android devices?
Based on the provided data, SARCULATOR is supported on iPhone, iPad, and iPod. Information regarding Android compatibility is not available.
What is the age rating for SARCULATOR?
SARCULATOR has an age rating of 12+, indicating it is suitable for users aged 12 and older.
How often is SARCULATOR updated?
The latest version of SARCULATOR is 3.0.2, which was last updated on May 1, 2026. This suggests a potentially infrequent update cycle.
What is the user sentiment for SARCULATOR?
SARCULATOR has a rating of 4.3 stars from 3 ratings, indicating generally positive user sentiment among its limited reviewer base.
Does SARCULATOR have ads?
No, SARCULATOR does not contain advertisements, as indicated by the 'hasAds' flag being false.
